Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab vs Methylprednisolone in COVID-19 CRS
NCT04377503Phase 2Terminated
- Sponsor
- Hospital São Domingos
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised trial of tocilizumab in cytokine release syndrome (CRS) (2 arms), sponsored by Hospital São Domingos. Primary endpoint: Patient clinical status at 15 days. Started May 2020; status: terminated.
02
Drugs
tocilizumab
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04377503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04377503.